Bilal Farooqi

Bilal Farooqi

Auto-generated profile, based on publicly available information

Bilal Farooqi

Department of Medicine, Mercer University School of Medicine, Macon, Georgia, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
BHBaoli Hu
Baoli Hu
Daniele GilkesDaniele Gilkes
Daniele Gilkes
BFBilal Farooqi
Bilal Farooqi
SSSaid M. Sebti
Said M. Sebti
JCJiandong Chen
Jiandong Chen
The p53 tumor suppressor plays a key role in maintaining genomic stability and protection against malignant transformation. MDM2 and MDMX are both p53-binding proteins that regulate p53 stability and activity. Recent development of the MDM2 inhibitor Nutlin 3 has greatly facilitated functional analysis of MDM2-p53 binding. We found that although MDMX is homologous to MDM2 and binds to the same region on p53 N terminus, Nutlin does not disrupt p53-MDMX interaction. The ability of Nutlin to activate p53 is compromised in tumor cells overexpressing MDMX. Combination of Nutlin with MDMX siRNA resulted in synergistic activation of p53 and growth arrest. These results suggest that MDMX is also a valid target for p53 activation in tumor cells. Development of novel compounds that are MDMX-specific or optimized for dual-inhibition of MDM2 and MDMX are necessary to achieve full activation of p53 in tumor cells.

31 March 2009 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
ASAlex Shaginian
Alex Shaginian
LWLandon R. Whitby
Landon R. Whitby
SHSukwon Hong
Sukwon Hong
IHInkyu Hwang
Inkyu Hwang
BFBilal Farooqi
Bilal Farooqi
DBDale L. Boger
Dale L. Boger

31 August 2005 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
JMJustin K. Murray
Justin K. Murray
BFBilal Farooqi
Bilal Farooqi
JSJack D. Sadowsky
Jack D. Sadowsky
MSMark Scalf
Mark Scalf
WFWesley A. Freund
Wesley A. Freund
SGSamuel H. Gellman
Samuel H. Gellman

1 June 2005 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
LCLihong Chen
Lihong Chen
HYHang Yin
Hang Yin
BFBilal Farooqi
Bilal Farooqi
SSSaid Sebti
Said Sebti
AHAndrew D. Hamilton
Andrew D. Hamilton
JCJiandong Chen
Jiandong Chen
Overexpression or hyperactivation of MDM2 contributes to functional inactivation of wild-type p53 in nearly 50% of tumors. Inhibition of p53 by MDM2 depends on binding between an NH2-terminal (residues 16–28) p53 α-helical peptide and a hydrophobic pocket on MDM2, presenting an attractive target for development of inhibitors against tumors expressing wild-type p53. Here we report that novel p53 α-helical peptide mimics based on a terphenyl scaffold can inhibit MDM2-p53 binding in vitro and activate p53 in vivo. Several active compounds have been identified that inhibit MDM2-p53 binding in an ELISA assay with IC50 of 10 to 20 μmol/L and induce p53 accumulation and activation in cell culture at 15 to 40 μmol/L. These results suggest that p53 α-helical mimetics based on the terphenyl scaffold may be developed into potent p53 activators.

18 November 2016 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
YHYvonne Hewett
Yvonne Hewett
SGSubash Ghimire
Subash Ghimire
BFBilal Farooqi
Bilal Farooqi
BSBinay K Shah
Binay K Shah
Lenvatinib, an oral multikinase inhibitor, was approved by the US Food and Drug Administration in February 2015. In a pivotal phase III study of 392 patients with progressive radioiodine-refractory thyroid cancer, the overall response rate of patients receiving lenvatinib was 64.8%, with complete response in four patients. The median progression-free survival was 18.3 months in the lenvatinib arm versus 3.6 months in patients receiving placebo. Median overall survival was not reached in either arm. Lenvatinib is a promising new treatment for patients with radioiodine (iodine-131)-refractory differentiated thyroid cancer.

1 September 2015 in The American Journal of the Medical Sciences
Verified
Journal Article
Closed access
PDF file
MCMudit Chowdhary
Mudit Chowdhary
BFBilal Farooqi
Bilal Farooqi
RPRafael Ponce-Terashima
Rafael Ponce-Terashima